MK615 decreases RAGE expression and inhibits tage-induced proliferation in hepatocellular carcinoma cells

World Journal of Gastroenterology

Volumn 16, Issue 42, 2010, Pages 5334-5341

  Sakuraoka, Yuhki ^a   Sawada, Tokihiko ^a   Okada, Toshie ^a   Shiraki, Takayuki ^a   Miura, Yoshikazu ^a   Hiraishi, Katsuya ^b   Ohsawa, Tatsushi ^b   Adachi, Masakazu ^b   Takino, Jun ichi ^c   Takeuchi, Masayoshi ^c   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Ada Bio Co Ltd   (Japan)

^c HOKURIKU UNIVERSITY   (Japan)

Author keywords

Advanced glycation endproducts; Hepatocellular carcinoma; MK615; Receptor of advanced glycation end product; Toxic advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BOVINE SERUM ALBUMIN; GLUCOSE; GLYCERALDEHYDE; INDOMETACIN; MESSENGER RNA;

APOPTOSIS; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 78649441343     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i42.5334     Document Type: Article

References (28)

1. Nakagawa A, Sawada T, Okada T, Ohsawa T, Adachi M, Kubota K. New antineoplastic agent, MK615, from UME (a Variety of) Japanese apricot inhibits growth of breast cancer cells in vitro. Breast J 2007; 13: 44-49
2. Mori S, Sawada T, Okada T, Ohsawa T, Adachi M, Keiichi K. New anti-proliferative agent, MK615, from Japanese apricot Prunus mume induces striking autophagy in colon cancer cells in vitro. World J Gastroenterol 2007; 13: 6512-6517
3. Okada T, Sawada T, Osawa T, Adachi M, Kubota K. A novel anti-cancer substance, MK615, from ume, a variety of Japanese apricot, inhibits growth of hepatocellular carcinoma cells by suppressing Aurora A kinase activity. Hepatogastroenterology 2007; 54: 1770-1774
4. Okada T, Sawada T, Osawa T, Adachi M, Kubota K. MK615 inhibits pancreatic cancer cell growth by dual inhibition of Aurora A and B kinases. World J Gastroenterol 2008; 14: 1378-1382
5. Kawahara K, Hashiguchi T, Masuda K, Saniabadi AR, Kikuchi K, Tancharoen S, Ito T, Miura N, Morimoto Y, Biswas KK, Nawa Y, Meng X, Oyama Y, Takenouchi K, Shrestha B, Sameshima H, Shimizu T, Adachi T, Adachi M, Maruyama I. Mechanism of HMGB1 release inhibition from RAW264.7 cells by oleanolic acid in Prunus mume Sieb. et Zucc. Int J Mol Med 2009; 23: 615-620
6. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251
7. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
8. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 2003; 23: 129-134
9. Hudson BI, Schmidt AM. RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm Res 2004; 21: 1079-1086
10. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2006; 21: 197-208
11. Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, Nonaka M, Nabeshima Y, Inoue M, Ishitobi T, Chayama K, Tazuma S. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 1112-1119
12. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360
13. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Makita Z. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol Med 2002; 8: 546-550
14. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Koga K, Sasaki N, Yamamoto H, Takeuchi M, Makita Z. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 2002; 290: 973-978
15. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001; 50: 1495-1504
16. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16: 1928-1930
17. Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, Kameda Y, Makita Z. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol 2000; 59: 1094-1105
18. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, Sasaki N, Yamagishi S, Takeuchi M, Shimizu H. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004; 122: 461-467
19. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008; 14: 940-945
20. Morimoto Y, Kikuchi K, Ito T, Tokuda M, Matsuyama T, Noma S, Hashiguchi T, Torii M, Maruyama I, Kawahara K. MK615 attenuates Porphyromonas gingivalis lipopolysaccharide- induced pro-inflammatory cytokine release via MAPK inactivation in murine macrophage-like RAW264.7 cells. Biochem Biophys Res Commun 2009; 389: 90-94
21. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000; 6: 114-125
22. Takeuchi M, Yanase Y, Matsuura N, Yamagishi Si S, Kameda Y, Bucala R, Makita Z. Immunological detection of a novel advanced glycation end-product. Mol Med 2001; 7: 783-791
23. Okada T, Sawada T, Kubota K. Deferoxamine enhances anti-proliferative effect of interferon-gamma against hepatocellular carcinoma cells. Cancer Lett 2007; 248: 24-31
24. Hiwatashi K, Ueno S, Abeyama K, Kubo F, Sakoda M, Maruyama I, Hamanoue M, Natsugoe S, Aikou T. A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann Surg Oncol 2008; 15: 923-933
25. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097-1109
26. Yamamoto Y, Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi A, Takeuchi M, Yamamoto H. Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract 2007; 77 Suppl 1: S30-S40
27. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 2006; 6: 351-358
28. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis 2009; 16: 845-858